Randomized trial demonstrates drug-drug interaction predictions in pharmaceuticals, indicating enhanced drug safety and optimized dosage.
In modern pharmaceuticals, Physiologically Based Pharmacokinetic (PBPK) modelling has emerged an essential technique used in the estimation of drug - drug interaction. The technique incorporates physiological, biochemical, and pharmacological informations to know the pharmacokinetics of the drugs in a virtual physiological system. It offers a superior alternative compared to other pharmacokinetic modeling techniques. There is an increasing use of PBPK models in estimating DDI, as it allows evaluation of how a drug interacts with the body in the absorption, metabolism, and elimination of other drugs. Such predictions enhance drug safety and optimize drug dosage without requiring many experiments. Pharmacokinetic models are currently supported by several software like Simcyp, GastroPlus, and PK-Sim, among others, and this has made PBPK modeling more accepted in regulatory processes during drug approvals. Still, there are various limitations associated with PBPK modeling such as lack of accurate data.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: